Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
8.26
-0.14 (-1.67%)
At close: Sep 15, 2026, 4:00 PM EDT
8.29
+0.03 (0.36%)
After-hours: Sep 15, 2026, 7:30 PM EDT
Arvinas Revenue
Arvinas had revenue of $249.70M in the quarter ending June 30, 2026, with 1,014.73% growth. This brings the company's revenue in the last twelve months to $316.70M, down -15.05% year-over-year. In the year 2025, Arvinas had annual revenue of $262.60M, down -0.30%.
Revenue (ttm)
$316.70M
Revenue Growth
-15.05%
P/S Ratio
1.71
Revenue / Employee
$1,287,398
Employees
246
Market Cap
540.09M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 262.60M | -800.00K | -0.30% |
| Dec 31, 2024 | 263.40M | 184.90M | 235.54% |
| Dec 31, 2023 | 78.50M | -52.90M | -40.26% |
| Dec 31, 2022 | 131.40M | 77.80M | 145.15% |
| Dec 31, 2021 | 53.60M | 27.70M | 106.95% |
| Dec 31, 2020 | 25.90M | -17.10M | -39.77% |
| Dec 31, 2019 | 43.00M | 28.68M | 200.20% |
| Dec 31, 2018 | 14.32M | 6.75M | 89.00% |
| Dec 31, 2017 | 7.58M | 909.85K | 13.64% |
| Dec 31, 2016 | 6.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| REGENXBIO | 174.48M |
| Assembly Biosciences | 74.85M |
| OmniAb | 38.46M |
| Scribe Therapeutics | 33.30M |
| Opus Genetics | 9.86M |
| Prime Medicine | 4.07M |
| Ovid Therapeutics | 1.58M |
| ProKidney | 818.00K |
ARVN News
- 5 days ago - Arvinas Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 7 days ago - Arvinas Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 12 days ago - Arvinas to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 14 days ago - Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Arvinas price target lowered to $10 from $11 at Morgan Stanley - TheFly
- 5 weeks ago - Arvinas price target lowered to $14 from $19 at Evercore ISI - TheFly
- 5 weeks ago - Arvinas price target lowered to $21 from $24 at Citi - TheFly
- 5 weeks ago - Arvinas price target raised to $12 from $11 at Wedbush - TheFly